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Objective: To assess the prevalence levels of awareness, treatment and control of hypertension and associated factors 
in Switzerland. 
Methods: Population-based cross-sectional study of 6,182 subjects (52.5% women) aged 35-75 years living in 
Lausanne, Switzerland. Hypertension was defined as blood pressure ≥140/90 mm Hg or current antihypertensive 
medication. 
Results: The overall prevalence of hypertension was 36% (95% CI: 35-38%). Among hypertensive participants, 63% 
were aware of having hypertension. Among aware hypertensives, 78% were treated, and among treated hypertensives 
48% were controlled (BP <140/90 mmHg). In multivariate analysis, prevalence of hypertension was associated with 
older age, male gender, low educational level, high alcohol intake, awareness of diabetes, awareness of dyslipidaemia, 
obesity and parental history of myocardial infarction (MI). Awareness of hypertension was associated with older age, 
female gender, awareness of diabetes, awareness of dyslipidaemia, obesity and parental history of MI. Control was 
associated with younger age, higher educational level and no alcohol intake. Alone or in combination, sartans were the 
most often prescribed antihypertensive medication category (41%), followed by diuretics, beta-blockers, ACE 
inhibitors and calcium channel blockers. Only 31% of treated hypertensives were taking ≥2 antihypertensive 
medications. 
Conclusion: Although more than half of the participants with hypertension were aware of being hypertensive and 
more than three quarters of them received a pharmacological treatment, less than half of those treated were adequately 
controlled. Treated hypertensive subjects should be followed up more closely.  
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CHUV RESEARCH DAY 2008 
Thursday, January 17th, 2008 
“Regenerative Medicine” 
 
 
 
08:30 Presentation of the 2008 Research Day 
Professor Ivan Stamenkovic, Vice Dean for Research  
    
08:45 Keynote 
speaker 1 
 
 
 
Professor Philippe Menasché 
Department of Cardio-Vascular Surgery 
Hôpital Européen G. Pompidou, Paris 
“Promises and pitfalls of skeletal myoblast therapy” 
    
09:30 Coffee & Posters   
    
10:30 6 short talks   
    
12:00 Keynote 
speaker 2 
 
 
Professor Giulio Cossu 
Stem Cell Research Institute, Milano 
“Towards a cell therapy for muscular dystrophy” 
    
12:45 Lunch, Coffee & Posters  
    
14:00 Keynote 
speaker 3 
 
Professor Michele De Luca 
Department of Biomedical Sciences, Modena 
Epithelial Stem Cell Research Centre, Venice 
“Epithelial stem cells and regenerative medicine” 
    
14:45 6 short talks   
    
16:15 Coffee & Posters  
    
17:00 Keynote 
speaker 4 
 
Professor Lior Gepstein 
Dept of Physiology & Biophysics, Technion – Haifa, 
Israel 
“Myocardial Regeneration by Human Embryonic 
Stem Cells” 
    
17:45 Poster Prizes Ceremony  
    
18:00 Apéritif & Buffet  
 
ATTENDANCE IS FREE - NO REGISTRATION IS NECESSARY 
   
NOTE: Posters will be displayed from  
Wednesday January 16st early morning  to Friday January 18th  early morning. 
 
 
  
 
 
 
 
12 short talks 
 
 
Schedule 
 
 
Names, departments 
 
 
Titles 
 
 
Morning 
 
10h30 - 10h45 Boris Hinz 
Laboratoire de biophysique 
cellulaire - EPFL 
“The myofibroblast - friend and foe in tissue 
regeneration” 
10h45 – 11h00 Matthias Lutolf  
Laboratoire de cellules souches et 
bioengineering - EPFL 
 
"Bioengineering artificial stem cell niches".  
11h00 – 11h15 Corinne Kostic 
Unité de thérapie génique et 
biologie des cellules souches – 
Hôpital Ophtalmique 
"Gene therapy preclinical studies for Leber 
congenital amaurosis" 
 
11h15 – 11h30 Anne Zurn 
Chirurgie expérimentale - CHUV 
“Delayed peripheral nerve priming improves 
regeneration of sensory axons 
into the spinal cord following dorsal root 
injury.” 
 
11h30 – 11h45 Meta Djojosubroto  
Unité de thérapie génique et 
biologie des cellules souches – 
Hôpital Ophtalmique 
“Increased chromosomal aberrations and 
transformation of adult mouse retinal stem 
cells” 
11h45 – 12h00 Paola Bonfanti 
Chirurgie expérimentale - CHUV & 
Laboratoire de dynamique des 
cellules souches - EPFL 
 
“Thymic epithelial cells have skin potency” 
 
Afternoon 
 
14h45 – 15h00 Dominique Pioletti 
Laboratoire de biomécanique en 
orthopédie - EPFL 
“In Vivo evaluation of human fetal cells as 
allogenic cell source for tissue engineering” 
 
15h00 – 15h15 Mikaël Martino 
Laboratoire de médecine 
régénérative et de 
pharmacobiologie - EPFL 
“Controlling mesenchymal stem cells response 
to biomaterials with recombinant integrin-
specific fibronectin fragments” 
 
15h15 – 15h30 Dela Golshayan 
Nephrologie et Centre de 
Transplantation d’organes - CHUV 
 
“Mechanisms of Allograft rejection and 
tolerance in transplantation” 
 
15h30 - 15h45 Jonathan Bloch 
Médecine Interne - CHUV 
"Spleen derived vascular progenitor cell 
transfer restores metabolic and vascular 
insulin sensitivity in high-fat diet insulin 
resistant mice" 
 
15h45 - 16h00 Marc-Etienne Roehrich 
Cardiologie – CHUV  
“Immunophenotypical analysis of putative 
cardiac progenitor cells isolated 
based on high ALDH activity from adult 
mouse and human hearts” 
 
16h00 – 16h15 Mohamed Nemir 
Dpt de Médecine - CHUV 
"Control of cardiac integrity via the Notch1 
receptor pathway". 
 
